US2007203241A1PendingUtilityA1
Antiviral treatments
Est. expiryFeb 13, 2026(expired)· nominal 20-yr term from priority
A61P 31/16A61P 31/12A61K 31/196A61K 31/195A61K 9/006A61K 31/215A61K 45/06A61K 9/0019
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
Claims
exact text as granted — not AI-modified1 . A method for treating a viral infection in a human comprising administering an effective anti-viral amount of a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof, to the human by an intravenous route.
2 . The method of claim 1 , wherein the compound of formula I, II, III, or IV is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
3 . The method of claim 1 , wherein the viral infection is an influenza infection.
4 . The method of claim 3 , wherein the viral infection is an influenza type A or type B infection.
5 . The method of claim 1 , wherein the viral infection is caused by a strain of virus represented by the formula H x N y wherein X is an integer from 1-16 and Y is an integer from 1-9.
6 . The method of claim 3 , wherein the influenza is an H3N2, H1N1, H 5 N1, avian, or seasonal influenza.
7 . The method of claim 1 , wherein the effective anti-viral amount is up to about 800 mg.
8 . The method of claim 7 , wherein the effective anti-viral amount is up to about 400 mg.
9 . The method of claim 8 , wherein the effective anti-viral amount is up to about 300 mg.
10 . The method of claim 9 , wherein the effective anti-viral amount is up to about 200 mg.
11 . The method of claim 1 , wherein the entire effective dose is administered in one intravenous administration.
12 . The method of claim 1 , wherein the entire effective dose is administered in multiple intravenous administrations.
13 . The method of claim 2 , wherein a compound or formula Ia, or a pharmaceutically acceptable salt thereof, is administered.
14 . The method of claim 1 , wherein the plasma concentration of the compound is higher than the IC 50 of the virus causing the viral infection 12 hours following administration of the compound.
15 . A method for inhibiting a neuraminidase in a human comprising administering an effective inhibitory amount of a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof, to the human by an intravenous route.
16 . The method of claim 15 , wherein the compound of formula I, II, III, or IV is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
17 . The method of claim 15 , wherein the effective inhibitory amount is up to about 800 mg.
18 . The method of claim 17 , wherein the effective inhibitory amount is up to about 400 mg.
19 . The method of claim 18 , wherein the effective inhibitory amount is up to about 300 mg.
20 . The method of claim 19 , wherein the effective inhibitory amount is up to about 200 mg.
21 . The method of claim 15 , wherein the entire effective inhibitory dose is administered in one intravenous administration.
22 . The method of claim 15 , wherein the entire effective inhibitory dose is administered in multiple intravenous administrations.
23 . The method of claim 16 , wherein a compound of formula Ia, or a pharmaceutically acceptable salt thereof, is administered.
24 . The method of claim 1 , further comprising orally administering a neuraminidase inhibitor to the human.
25 . The method of claim 24 , wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate.
26 . The method of claim 24 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof.
27 . The method of claim 24 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
28 . The method of claim 27 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, or a pharmaceutically acceptable salt thereof.
29 . The method of claim 24 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days.
30 . The method of claim 29 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 10 days.
31 . The method of claim 30 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days.
32 . A unit dosage form that is suitable for intravenous administration to a human, comprising up to about 800 mg of a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof.
33 . The unit dosage form of claim 32 , wherein the compound of formula I, II, III, or IV is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
34 . The unit dosage form of claim 32 that comprises up to about 400 mg of the compound or salt.
35 . The unit dosage form of claim 34 that comprises up to about 300 mg of the compound or salt.
36 . The unit dosage form of claim 35 that comprises up to about 200 mg of the compound or salt.
37 . A kit, comprising packaging materials, a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof, and instructions for administering the compound to a human by an intravenous route.
38 . The kit of claim 37 , wherein the compound is provided in a formulation suitable for intravenous administration.
39 . The kit of claim 37 that comprises up to about 800 mg of the compound or salt.
40 . The kit of claim 39 that comprises up to about 400 mg of the compound or salt.
41 . The kit of claim 40 that comprises up to about 300 mg of the compound or salt.
42 . The kit of claim 41 that comprises up to about 200 mg of the compound or salt.
43 . A kit, comprising packaging materials, a unit dosage form as described in claim 32 , and instructions for administering the compound to a human by an intravenous route.
44 - 80 . (canceled)
81 . The method of claim 15 , further comprising orally administering a neuraminidase inhibitor to the human.
82 . The method of claim 81 , wherein the neuraminidase inhibitor that is administered orally is oseltamivir carboxylate.
83 . The method of claim 81 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof.
84 . The method of claim 81 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, IIa, IIIa, or IVa:
or a pharmaceutically acceptable salt thereof.
85 . The method of claim 84 , wherein the neuraminidase inhibitor that is administered orally is a compound of formula Ia, or a pharmaceutically acceptable salt thereof.
86 . The method of claim 81 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 20 days.
87 . The method of claim 86 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 10 days.
88 . The method of claim 87 , wherein the neuraminidase inhibitor that is administered orally is administered for up to 5 days.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.